TI
ABCL icon

TrueMark Investments’s AbCellera Biologics ABCL Stock Holding History

TrueMark Investments’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-111,119
Closed -$381K – 196
2025
Q2 		$381K Sell
111,119
-4,272
-4% -$10.6K 0.08% 131
2025
Q1 		$257K Sell
115,391
-8,698
-7% -$24.9K 0.07% 140
2024
Q4 		$364K Sell
124,089
-10,325
-8% -$28.8K 0.12% 117
2024
Q3 		$349K Buy
134,414
+24,457
+22% +$67.8K 0.11% 155
2024
Q2 		$325K Hold
109,957
– – 0.11% 157
2024
Q1 		$498K Buy
109,957
+13,104
+14% +$66.9K 0.46% 50
2023
Q4 		$553K Buy
+96,853
New +$449K 0.55% 50

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

TrueMark Investments's ABCL Position: Q3 2025 in Review

TrueMark Investments sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 111,119 shares — an estimated $381K sold.

TrueMark Investments first reported a position in ABCL in Q4 2023 and held it in 7 quarters. The position peaked at $553K in Q4 2023. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

  • TrueMark Investments reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
  • TrueMark Investments sold 111,119 AbCellera Biologics shares in Q3 2025, an estimated $381K.
  • TrueMark Investments first reported a position in AbCellera Biologics in Q4 2023 and held it in 7 quarters.
  • TrueMark Investments's AbCellera Biologics position peaked at $553K in Q4 2023.
  • 141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on TrueMark Investments's 13F filing for Q3 2025, filed 30 Oct 2025.